肝癌肝移植前降期治疗的研究进展  

Research progress in downstaging treatment of hepatocellular carcinoma before liver transplantation

作　　者：王建军[1] 柴楚星 孙释然 唐勇 熊俊[1] 万赤丹 Wang Jianjun;Chai Chuxing;Sun Shiran;Tang Yong;Xiong Jun;Wan Chidan(Union Hospital of Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院,武汉430022

出　　处：《中华肝胆外科杂志》2021年第4期305-309,共5页Chinese Journal of Hepatobiliary Surgery

摘　　要：对符合肝移植标准的肝癌患者,肝移植是一种有效的根治性治疗方案。然而,大部分患者就诊时肿瘤进展已超出移植标准,使得这部分患者难以从肝移植中获益。通过局部或全身治疗手段,对肝癌进行降期治疗,减轻患者肿瘤负荷,使超出移植标准的患者经治疗后符合移植标准,让更多患者有希望接受肝移植治疗。目前,肝癌肝移植前降期治疗已被广泛接受。在此,对肝癌肝移植前降期治疗的指征、治疗方案的选择、治疗终点及治疗效果进行综述。Liver transplantation is an effective curative treatment for hepatocellular carcinoma patients.However,most patients lost the change of surgery when diagnosed as hepatocellular carcinoma.Through local or systemic treatment,hepatocellular carcinoma can be treated in a downstaging manner to reduce tumor burden,so that patients who are beyond the transplantation criteria can still be up to the transplantation criteria after treatment,and finally receive liver transplantation.At present,pre-transplant downstaging treatment has been widely accepted.In this review,we summarized the indications,treatment options,treatment endpoints,and treatment outcomes of pre-transplant downstaging treatment.

关 键 词：肝肿瘤 肝移植 降期 

分 类 号：R735.7[医药卫生—肿瘤]